Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 17, 2022

SELL
$20.42 - $28.13 $349,182 - $481,023
-17,100 Reduced 40.62%
25,000 $588,000
Q4 2021

Feb 15, 2022

BUY
$25.89 - $33.45 $613,593 - $792,765
23,700 Added 128.8%
42,100 $1.15 Million
Q2 2021

Aug 16, 2021

SELL
$24.17 - $36.01 $183,692 - $273,676
-7,600 Reduced 29.23%
18,400 $524,000
Q1 2021

May 18, 2021

BUY
$32.28 - $44.3 $187,224 - $256,939
5,800 Added 28.71%
26,000 $886,000
Q4 2020

Feb 17, 2021

SELL
$31.45 - $40.54 $2.9 Million - $3.74 Million
-92,200 Reduced 82.03%
20,200 $672,000
Q3 2020

Nov 17, 2020

BUY
$26.0 - $34.5 $1.8 Million - $2.38 Million
69,100 Added 159.58%
112,400 $3.61 Million
Q2 2020

Aug 17, 2020

BUY
$14.11 - $29.42 $245,514 - $511,908
17,400 Added 67.18%
43,300 $1.19 Million
Q3 2017

Nov 14, 2017

BUY
$11.61 - $31.21 $300,699 - $808,339
25,900
25,900 $808,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.82B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.